Paul Stamets Psilocybin Mushrooms and The Mycology of Consciousness
01:07:43 min
CLEAR ALL
1
A six-day global gathering of the international scientific community in Oakland, California to explore new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.
Roland R. Griffiths, Ph.D. is a psychopharmacologist who serves as a professor and research coordinator at the Johns Hopkins University School of Medicine. This interview was captured during the Psychedemia conference at the University of Pennsylvania in September 2012.
In this edited version of Roland Griffith’s very information talk on Psilocybin (original title “The science of psilocybin and its use to relieve suffering”) we take a look at the amazing positive effects achieved with this controversial substance.
This presentation summarizes past and ongoing studies from the Johns Hopkins Psilocybin Research Project, which started about 15 years ago.
Bestselling author Tim Ferriss (Tools of Titans, The 4-Hour Workweek, etc.) probes the science, mysteries, and future of psychedelics with Dr. Roland R. Griffiths, a clinical pharmacologist at Johns Hopkins. Dr.
Dr Robin Carhart-Harris talks about his scientific research into the effects and potential therapeutic uses of psychedelic drugs. Join him as he discusses brain imaging work involving psilocybin, the active ingredient of magic mushrooms, and explains how the drug works in the brain.
Psychedelics have an ancient and more recent history of medicinal-use. Administered in a supportive environment, with preparatory and integrative psychological care, psychedelic medicines are now being used to facilitate emotional breakthrough and renewed perspective.
REBUS and the Anarchic Brain: A Unified Model of the Brain Action of Psychedelics Robin Carhart-Harris moved to Imperial College London in 2008 after obtaining a PhD in Psychopharmacology from the University of Bristol and an MA in Psychoanalysis from Brunel University.
Abstract: Highlighting the results of two fMRI studies and one MEG study with psilocybin and an fMRI study with MDMA, Carhart-Harris will report the effects of both drugs on regional brain activity and brain network organization.